What Is ARA-290 (Cibinetide)?

ARA-290 is a synthetic 11-amino-acid peptide derived from a region of the erythropoietin (EPO) sequence, also referred to in the literature as cibinetide. Researchers asking what is ARA-290 are generally looking at a non-hematopoietic EPO-derived peptide described as interacting with the innate repair receptor (IRR) rather than the receptor complex associated with red blood cell production. This page summarises what the compound is and which endpoints published laboratory work has examined.

The molecular origins of ARA-290

ARA-290 was engineered from erythropoietin, a glycoprotein characterised for its role in red blood cell formation through the homodimeric EPO receptor. Separate literature describes a distinct receptor configuration, referred to as the innate repair receptor, which is reported as a heteromer of the EPO receptor and the CD131 common beta-receptor subunit.

ARA-290 is an 11-amino-acid peptide whose structure corresponds to the B-helix region of the EPO molecule. It is described as lacking affinity for the homodimeric EPO receptor, which is the basis for the term non-hematopoietic in the published descriptions. Reported binding is instead to the IRR, which experimental work describes as upregulated under conditions of cellular stress rather than in resting tissue.

Receptor pathway examined in the literature

Work on ARA-290 research material centres on IRR engagement and the intracellular signalling measured downstream of it in defined experimental systems.

1. Cytokine measurements: studies report reduced levels of markers such as TNF-alpha and IL-6 in the models examined.
2. Signalling readouts: JAK2/STAT and PI3K/Akt pathway activity is reported in cell and animal models, alongside measures of mitochondrial membrane potential.
3. Neural-tissue endpoints: experimental work measures small-fibre and nerve-density readouts in animal and laboratory models.

This receptor-specific focus distinguishes it from peptides such as BPC-157, which is characterised in the literature through different signalling routes.

Reported research endpoints

A substantial portion of published ARA-290 work reports small-fibre and nerve-density measurements, including corneal nerve fibre density used as a quantitative proxy in study designs. Reported observations are confined to the model systems and measurement windows described in each paper.

Additional laboratory work reports metabolic and vascular endpoints, including glucose-handling measures and markers of inflammatory signalling in animal models. These are described here as measured study endpoints only, not as outcomes generalised beyond the systems studied.

Tissue-protection research models

Because the IRR is reported as expressed across several tissue types under stress conditions, experimental work has examined ARA-290 in ischaemia-reperfusion, renal, and cutaneous models. Reported measurements include extracellular-matrix characterisation and progenitor-cell recruitment at the site examined.

Where TB-500 literature centres on actin-mediated cell migration, ARA-290 work is framed around receptor-mediated signalling and inflammatory-marker measurement in the same broad model categories.

Comparison with related research compounds

Within cytoprotective research, ARA-290 is characterised narrowly by its receptor pathway. It is commonly contrasted with:

* [BPC-157](/research/hubs/bpc-157): examined through nitric oxide and angiogenic signalling readouts. * [SS-31](/research/hubs/ss-31): a mitochondria-targeted peptide studied through cardiolipin interaction rather than receptor-mediated signalling. * [Glutathione](/catalog/glutathione): studied through redox and antioxidant chemistry rather than receptor engagement.

Material handling in the laboratory

ARA-290 is supplied as a lyophilized powder. Peptide material of this class is sensitive to temperature and physical agitation, and handling should follow the documentation supplied with the received batch.

* Form: sealed lyophilized powder in a glass vial. * Storage: kept refrigerated, dry, and protected from light per batch documentation. * Verification: match the identifier on the received unit through the public batch lookup and review the published verification standards.

Limitations and research gaps

Published ARA-290 work carries clear limitations. Circulating half-life is reported as short, with intracellular signalling described as persisting beyond measurable plasma presence — a temporal decoupling that complicates pharmacokinetic study design.

Because IRR expression is reported as stress-dependent, ARA-290 shows negligible measurable activity in unstressed tissue, which makes establishing a baseline comparison difficult in non-pathological models. Longer-duration data are limited, the effect on immune-surveillance readouts over extended periods is not well characterised, and synthesis cost plus frequent-administration requirements constrain large-scale preclinical designs.

Frequently asked questions

Q: Does ARA-290 engage the erythropoietic receptor? The literature describes ARA-290 as lacking affinity for the homodimeric EPO receptor associated with red blood cell formation; reported binding is to the innate repair receptor.

Q: How does ARA-290 differ structurally from EPO? EPO is a full-length glycoprotein. ARA-290 is an 11-amino-acid peptide corresponding to one structural region of that molecule.

Q: Which models appear most often in ARA-290 literature? Small-fibre and nerve-density models, ischaemia-reperfusion models, and metabolic models in animal and cell systems.

Q: Is an analytical report attached for this material? No ARA-290 report file is attached to the catalog listing, so none is cited. Batch identifiers should be checked through the public lookup.

Research Use Only. This content is intended for laboratory and research purposes only. Not for human consumption, diagnosis, or treatment.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.